Please assess the completion status of the following clinical trial:

Trial Title: Clinical Study to Determine if Ecopipam Can Reduce Urges to Gamble

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject must be diagnosed with Pathological Gambling according to DSMIV criteria~* Subject must have at least 2 episodes of gambling behavior within the previous 2 weeks before screening~* Subject must have gambling urges of at least moderate intensity~Exclusion Criteria:~* Subjects must not have unstable medical illness or clinically significant abnormalities on lab tests, ECG, or physical exam~* Subjects with major depressive episode within the last 2 years~* Subjects with a history of attempted suicide~* Subjects with first degree relative with major depressive episode that resulted in hospitalization, attempted or completed suicide~* Subjects with a history of epilepsy or seizures~* Subjects with a myocardial infarction (heart attack) with in the last 6 months~* Subjects with a lifetime history of bipolar disorder, dementia, schizophrenia, or any psychotic disorder~* Subjects with current of recent DSM-IV diagnosis of substance abuse or dependence (with the exception of nicotine)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Ecopipam (Type: EXPERIMENTAL): Ecopipam is a selective antagonist of one the classes of dopamine receptor.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo given first week of the study.

Based on this trial design, predict the completion outcome and termination type (if applicable).